BCIQ Profiles

Company Profile Report

Fighting cancer by mouth

How Vaximm's oral delivery tech may give its cancer vaccines an efficacy boost

With its first compound through Phase I, Vaximm AG has started to unveil the data and technology behind its preclinical pipeline of oral cancer vaccines. Using an attenuated Salmonella strain, the company is building a platform to create polyepitope vaccines against multiple tumor antigens, and co-opting the bacteria’s natural route of infection to deliver them.

On Tuesday, the company released an abstract ahead of this month’s AACR-NCI-EORTC conference demonstrating its technology can induce an immune response against multiple epitopes in mice. According to CEO Matthias Schroff, the constructs can hold up to 300 different epitopes, a key advantage for targeting neoantigens.

Last month, Vaximm disclosed for the first time data on its VXM10 program, and new data on its VXM06 program, which target PD-L1 and WT1 respectively, at the Third CRI-CIMT-EATI-AACR conference. In a mouse model of leukemia, the vaccines prevented or treated leukemia, depending on how early

Read the full 1464 word article

How to gain access

Continue reading with a
two-week free trial.